Literature DB >> 28224048

Wound Penetration of Cefazolin, Ciprofloxacin, Piperacillin, Tazobactam, and Vancomycin During Negative Pressure Wound Therapy.

Matthew P Rowan1, Krista L Niece1, Julie A Rizzo2, Kevin S Akers3.   

Abstract

Objective: Negative pressure wound therapy (NPWT) uses subatmospheric pressure as a noninvasive adjunct to treat wounds and has demonstrated clinical efficacy by accelerating healing of a variety of acute and chronic wounds. NPWT may also play a role in preventing or treating wound infections, possibly by increasing wound penetration of antibiotics. However, clinical data in patients undergoing antibiotic and NPWT treatment are limited. Approach: To evaluate the wound penetration of antibiotics in NPWT patients, we conducted a prospective, observational study of burn and trauma patients treated with NPWT and systemic antibiotics. We evaluated the plasma pharmacokinetic profile of systemic vancomycin, ciprofloxacin, cefazolin, and piperacillin/tazobactam, as well as total and unbound antibiotic concentrations in wound exudate from the same patients.
Results: Data from 32 patients with 37 wounds undergoing NPWT demonstrated that vancomycin, ciprofloxacin, and piperacillin/tazobactam all penetrated wounds with exudate to plasma concentration ratios more than 0.8. Cefazolin did not penetrate wounds in patients undergoing NPWT as effectively, with an average exudate to plasma concentration ratio of 0.51. Innovation: Clinical data on the wound penetration of antibiotics in patients undergoing NPWT are limited, but these data suggest that antibiotics have different capacities for wound penetration during NPWT that should be considered when making clinical decisions.
Conclusion: This initial report suggests that (1) vancomycin, ciprofloxacin, and piperacillin/tazobactam effectively penetrate wounds during NPWT and (2) cefazolin as well as other antibiotics may not penetrate wounds during NPWT.

Entities:  

Keywords:  WoundVac; antibiotic; burn; exudate; pharmacokinetics; trauma

Year:  2017        PMID: 28224048      PMCID: PMC5286546          DOI: 10.1089/wound.2016.0698

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  30 in total

Review 1.  Negative-pressure therapy versus standard wound care: a meta-analysis of randomized trials.

Authors:  Daniel Suissa; Alain Danino; Andreas Nikolis
Journal:  Plast Reconstr Surg       Date:  2011-11       Impact factor: 4.730

2.  Measurements of wound edge microvascular blood flow during negative pressure wound therapy using thermodiffusion and transcutaneous and invasive laser Doppler velocimetry.

Authors:  Ola Borgquist; Erik Anesäter; Erik Hedström; Charles K Lee; Richard Ingemansson; Malin Malmsjö
Journal:  Wound Repair Regen       Date:  2011-10-19       Impact factor: 3.617

3.  Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.

Authors:  Seth R Bauer; Charbel Salem; Michael J Connor; Joseph Groszek; Maria E Taylor; Peilin Wei; Ashita J Tolwani; William H Fissell
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

4.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Protein binding of cefazolin is saturable in vivo both between and within patients.

Authors:  Jane W A Vella-Brincat; Evan J Begg; Carl M J Kirkpatrick; Mei Zhang; Stephen T Chambers; Kate Gallagher
Journal:  Br J Clin Pharmacol       Date:  2007-01-12       Impact factor: 4.335

6.  Vacuum-assisted closure: a new method for wound control and treatment: clinical experience.

Authors:  L C Argenta; M J Morykwas
Journal:  Ann Plast Surg       Date:  1997-06       Impact factor: 1.539

Review 7.  A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors:  Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

8.  The flaws of laser Doppler in negative-pressure wound therapy research.

Authors:  Nicolas Kairinos; Andrew McKune; Michael Solomons; Donald A Hudson; Delawir Kahn
Journal:  Wound Repair Regen       Date:  2014 May-Jun       Impact factor: 3.617

9.  Measurement of vancomycin hydrochloride concentration in the exudate from wounds receiving negative pressure wound therapy: a pilot study.

Authors:  Yukiko Ida; Hajime Matsumura; Masami Onishi; Sayaka Ono; Ryutaro Imai; Katsueki Watanabe
Journal:  Int Wound J       Date:  2014-03-28       Impact factor: 3.315

10.  Cefazolin concentration in surgically created wounds treated with negative pressure wound therapy compared to surgically created wounds treated with nonadherent wound dressings.

Authors:  Julia V Coutin; Otto I Lanz; Geraldine C Magnin-Bissel; Marion F Ehrich; Emily I Miller; Stephen R Werre; Thomas O Riegel
Journal:  Vet Surg       Date:  2014-06-24       Impact factor: 1.495

View more
  3 in total

1.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

2.  Vacuum sealing drainage combined with naso-intestinal and gastric decompression tubes for the treatment of esophagogastrostomy neck fistula.

Authors:  Chuan Tian; Kaihao Xu; Yanan Zhao; Yahua Li; Kunpeng Wu; Dechao Jiao; Xinwei Han
Journal:  J Cardiothorac Surg       Date:  2022-06-13       Impact factor: 1.522

Review 3.  Retained Negative Pressure Wound Therapy Foams as a Cause of Infection Persistence.

Authors:  Konstantinos Anagnostakos; Andreas Thiery; Ismail Sahan
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-09-10       Impact factor: 4.730

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.